COVID-19 therapeutics for low- and middle-income countries: a review of re-purposed candidate agents with potential for near-term use and impact

Daniel Maxwell¹, Kelly C. Sanders^{2, 3}, Oliver Sabot², Ahmad Hachem⁶, Alejandro Llanos-Cuentas⁴, Ally Olotu⁵, Roly Gosling², James B. Cutrell¹, Michelle S. Hsiang^{2,6,7}

Affiliations

¹Department of Medicine, University of Texas (UT) Southwestern Medical Center, Dallas, USA

²Pandemic Response Initiative, Institute for Global Health Sciences, University of California, San Francisco (UCSF), USA

³Department of Pediatrics, Stanford University, Stanford, USA

⁴Institute of Tropical Medicine Alexander von Humbolt (IMTAvH), Universidad Peruana Cayetano Heredia (UPCH), Lima, Peru

⁵Clinical Trials and Interventions Unit, Ifakara Health Institute, Bagamoyo, Tanzania

⁶Department of Pediatrics, UT Southwestern Medical Center, Dallas, USA

⁷Department of Pediatrics, UCSF

Correspondence to: Michelle Hsiang, MD MSc, Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, USA
michelle.hsiang@utsouthwestern.edu

Abstract word count: 244

Main text word count: 4975

Keywords: SARS-CoV-2, severe acute respiratory syndrome-coronavirus 2, drug, repositioned, LMIC

Number of figures: 2

Number of tables: 1

43 Abstract

44 Low- and middle-income countries (LMICs) face significant challenges in the control of
 45 COVID-19, given limited resources, especially for inpatient care. In a parallel effort to that for
 46 vaccines, the identification of therapeutics that have near-term potential to be available and easily
 47 administered is critical. Using the United States, European Union, and World Health Organization
 48 clinical trial registries, we reviewed COVID-19 therapeutic agents currently under investigation. The
 49 search was limited to oral or potentially oral agents, with at least a putative anti-SARS-CoV-2 virus
 50 mechanism, and with at least 3 registered trials. We describe the available evidence regarding
 51 agents that met these criteria and additionally discuss the need for additional investment by the
 52 global scientific community in large well-coordinated trials of accessible agents and their
 53 combinations in LMICs. The search yielded 636, 175, and 930 trials, in the US, EU, and WHO trial
 54 registers, respectively. These trials covered 17 oral or potentially oral repurposed agents that are
 55 currently used as antimicrobials and immunomodulatory therapeutics and therefore have
 56 established safety. The available evidence regarding proposed mechanism of actions, clinical
 57 efficacy, and potential limitations is summarized. We also identified the need for large well-
 58 coordinated trials of accessible agents and their combinations in LMICs. Several repurposed agents
 59 have potential to be safe, available, and easily administrable to treat COVID-19. To prevent COVID-
 60 19 from becoming a neglected tropical disease, there is critical need for rapid and coordinated effort
 61 in their evaluation and the deployment of those found to be efficacious.

62

63

64

65

66

67

68

69 Introduction

70 The coronavirus disease 2019 (COVID-19) pandemic is having devastating long-term health
71 and socioeconomic impact in low- and middle-income countries (LMICs). Worsening access to
72 essential services, such as immunizations and routine care for preventable and chronic diseases, is
73 also leading to excess all-cause mortality and morbidity¹. Although lower population density and
74 younger age demographics in some LMICs may be protective against high COVID-19 mortality², poor
75 health infrastructure, including a lack of hospital beds, health care providers and basic supplies, can
76 lead to overwhelmed local health systems with relatively few cases³. Effectively responding to
77 COVID-19 outbreaks in LMICs requires the development of new “playbooks” that are contextualized
78 and locally relevant; following the path of high-income countries will most likely lead to wasted
79 resources and ultimately poor epidemic control. Additionally, while vaccine research is moving
80 forward at an unprecedented pace^{4, 5}, numerous barriers to effective widespread deployment exist⁶,
81 ^{7, 8}. And even with large immunization campaigns, treatments for those who cannot or do not
82 receive the vaccine will still be needed. For many infectious diseases that are vaccine-preventable,
83 antimicrobials remain powerful tools (e.g. bacterial meningitis, varicella, influenza): investment in
84 pharmaceutical interventions should not be compromised in favor of vaccine development.

86 There is an urgent need for COVID-19 therapeutics that act early in the disease to prevent
87 progression or work as pre- or post-exposure prophylaxis, and others that can treat severely or
88 critically ill patients to prevent mortality. To date, we only have dexamethasone and possibly
89 remdesivir to treat moderate to severe disease, and early non-peer reviewed press reports of
90 improved patient outcomes with injectable monoclonal antibodies for mild illness. However, since
91 the start of the pandemic, researchers have been screening and studying hundreds of available
92 chemicals and drugs with antiviral properties that could be repurposed for treatment of COVID-19.
93 Many of the agents currently in study are used for other diseases and have known safety profiles,
94 which would allow for more rapid scale up of manufacturing at lower cost.

95

96 COVID-19 therapeutics must be of course be efficacious, but also accessible for patients in
97 LMICs who may not have easy access to health centers. Oral, transmucosal or transdermal agents
98 will be the easiest to administer at home or an outpatient clinic, followed by intranasal or inhaled
99 formulations through a metered dose inhaler (MDI); these agents are typically less expensive and
100 can be more widely distributed to patients. Subcutaneous, nebulized and intravenous formulations
101 are much less easily administered as they can only be given in the context of a hospital or infusion
102 center, and often require inpatient admission for administration. For example, the current
103 intravenous (IV) formulation of remdesivir has intrinsic barriers to use due to the need for inpatient
104 admission, particularly in countries with large rural populations that live far from health centers⁹.

105

106 Here we review current repurposed therapeutics candidates for treatment of COVID-19
107 currently in advanced clinical trials with potential for easy administration.

108

109 **Methods**

110 Using the term “COVID-19” and its associated synonyms (“COVID”, “SARS-CoV-2”, “severe
111 acute respiratory syndrome coronavirus 2”, “2019-nCoV”, “2019 novel coronavirus”, “Wuhan
112 coronavirus”), we searched for trials registered in the United States National Library of Medicine (US
113 NLM, clinicaltrials.gov), European Union Clinical Trials Register (EUCTR, clinicaltrialsregister.eu), and
114 the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP). These
115 results were filtered to exclude non-interventional trials. We then excluded agents with no expected
116 possibility of oral administration, that were rarely studied ($n < 3$ in WHO ICTRP), or were already part
117 of major guidelines, such as remdesivir.

118

119 **Results**

The results of the search as of January 14, 2021 are shown in Table 1. The search yielded 636, 175, and 930 trials, in the US, EU, and WHO trial registers, respectively; of these trials, 88, 4, and 72 were completed, respectively. As the WHO ICTRP is a combination of the US and EU and other registers such as the Chinese Clinical Trial Registry (ChiCTR), we present a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for the WHO ICTRP search (figure 1). There were 19 agents, of which 2 were grouped with another structurally similar agents. The final list of 17 oral or potentially oral repurposed agents are currently used as antimicrobials and immunomodulatory therapeutics and therefore have established safety. The agents with >100 trial registered in any of the registers included: hydroxychloroquine, interferon, lopinavir/ritonavir, favipiravir, and ivermectin. Below is a summary of the available evidence regarding each agent's class, proposed mechanism of action, clinical efficacy, and potential limitations.

Hydroxychloroquine (HCQ)

While many trials have been undertaken to investigate the antimalarial and rheumatologic therapeutic CQ and HCQ, a hydroxy derivative of CQ, for treatment of COVID-19, results thus far have been largely negative. Here we focused on HCQ which is less toxic than CQ and has been shown to be more active against SARS-CoV-2 in vitro¹⁰. The SOLIDARITY trial of the WHO has released interim results as a pre-print and found that none of the 4 treatments tested, including HCQ, reduced 28-day mortality, initiation of ventilation, or duration of hospitalization¹¹. More recently, the RECOVERY Collaborative found no difference in 28-day mortality in 1,561 patients randomized to HCQ or usual care¹². Of note, median duration of symptoms at time of randomization was 9 days. Considering earlier treatment, again no difference in symptoms found when randomizing 491 patients to early treatment¹³. For prophylaxis, dozens of other trials are underway. One trial of post-exposure prophylaxis in community members and health workers found it to be ineffective¹⁴, though there were limitations of this pragmatic trial¹⁵. Another double-blind, placebo-controlled randomized clinical trial among healthcare workers showed no difference between post exposure

prophylaxis of HCQ (600 mg daily for 8 weeks) versus placebo¹⁶. Another randomized trial of 1483 healthcare workers showing no reduction in incidence of COVID-19 using once or twice weekly HCQ pre-exposure prophylaxis¹⁷. In summary, all phases of illness have been studied and HCQ has not been found to be effective to date.

Azithromycin

This macrolide antibiotic has been demonstrated to have a high selectivity index, based on half-maximal inhibitory concentration (IC50) divided by maximal cytotoxic concentration (CC50)¹⁸. However, in large randomized controlled trials (RCTs) it has been combined with HCQ or CQ and this combination has not shown to be of benefit, and has even shown signals of harm^{19, 20, 21, 22}. While no high-quality RCTs of azithromycin alone are available yet, a trial of mass administration to children in Niger resulted in 8 to 14-fold reductions in various coronaviruses based on PCR of the nasopharynx²³. Further results from at least one large RCT are expected²⁴.

Interferons (particularly beta-1a and beta-1b)

As cytokine mediators that trigger the cellular immune response to viral infections,²⁵ interferons have been used and studied as antiviral therapy for several viral infections²⁶. SARS-CoV-2 particularly has been shown to induce particularly low levels of interferon-1²⁷. The IC50 of IFN beta-1a against SARS-CoV-2 was found *in vitro* using Vero E6 to increase with time from infection²⁸. However, even as late as 96 hours from infection, high concentrations of IFN beta-1a, in the 50 to 5000 IU/mL range, completely protected Vero E6 cells. Notably, even at 5000 IU/mL, no morphological evidence of cytotoxicity due to IFN-beta-1a used in uninfected cells was noted. Clinically, IFN beta-1a has been evaluated in an open-label, randomized trial of 127 patients comparing LPV/r to triple therapy with LPV/r, IFN beta-1a, and ribavirin²⁹. Triple therapy, when administered in the first 7 days, was superior in symptom relief, shortening duration of viral shedding, and shortening duration of hospital stay, all with no difference in adverse events²⁹.

Subgroup analysis of the trial suggested that IFN beta-1b was the driver of clinical differences between groups. More recently, an Iranian trial of 81 patients comparing the national protocol of HCQ plus LPV/r or atazanavir-ritonavir versus the same protocol plus subcutaneous IFN beta-1a showed no change in time to clinical response (the primary outcome), but did demonstrate decreased 28-day mortality in the IFN beta-1a group (19 versus 43%, $p=0.015$)³⁰. However, the SOLIDARITY trial did not show any benefit in mortality, progression to ventilation, or duration of hospitalization¹¹.

Lopinavir/ritonavir

Lopinavir is a well-studied protease inhibitor used to treat HIV type 1. It is administered in combination with ritonavir, a cytochrome P450 inhibitor, to increase its plasma half-life. As lopinavir/ritonavir (LPV/r) was identified as having *in vitro* activity against SARS-CoV, this agent was used in an open-label clinical trial in a Wuhan hospital (n=199), with participants randomized to LPV/r or standard of care (SOC)³¹. While there was a trend toward lower mortality (19.2% vs 25%), it was not statistically significant. It should be noted that 3 of the 19 patients who died in the experimental arm died less than 24 hours after randomization and never received LPV/r. However, the RECOVERY collaborative found in a large, multicenter randomized trial that this treatment was not associated with reduction in 28-day mortality, duration of hospitalization, or progression to ventilation or death¹⁵.

Favipiravir

Favipiravir is another nucleoside analogue shown to have *in vitro* activity against SARS-CoV-2 in Vero cells, with an IC₅₀ of 61.88 μM ³². Given the CC₅₀ of >400 μM , this yields a SI of > 6.46. While this SI is less favorable than remdesivir's SI of >129.87, favipiravir was demonstrated to be 100% effective in a post-exposure prophylaxis mouse model after challenge with aerosolized Ebola virus, a virus for which it has a similar IC₅₀^{33, 34}. Clinical data on favipiravir for SARS-CoV-2 are still limited. A

trial of 80 patients compared favipiravir with interferon alpha against lopinavir/ritonavir with interferon alpha. While the favipiravir group had shorter time to viral clearance (4 vs 11 days), more frequent improvement in chest imaging (91 vs 62%) and fewer adverse events (11% vs 55%), these results are limited by lack of blinding and randomization³². An open-label, multicenter phase 3 clinical trial randomized 150 patients with mild to moderate COVID-19 to favipiravir versus standard of care, with a reported faster time to clinical cure and viral clearance by press release although the full data has not yet been published³⁵.

Ivermectin

Given its wide safety margin, ivermectin has been used broadly in mass distribution campaigns to treat illnesses such as onchocerciasis and lymphatic filariasis. More recently, it has been found to limit infection by dengue virus, West Nile Virus, and influenza, with antiviral activity attributed to inhibition of RNA virus interactions with the host nuclear transport proteins³⁶. Ivermectin has been tested *in vitro* against SARS-CoV-2, demonstrating reduction in viral RNA in infected cells³⁶. However, concentrations needed to achieve viral activity appear to be much higher than what standard doses can achieve in serum. Nonetheless, the drug can concentrate to higher levels in lung^{37, 38}. Possible evidence of this may come from a double-blind, randomized trial of 363 patients with PCR-proven SARS-CoV-2 in Dhaka, Bangladesh. Though not yet in pre-print, the team reported benefit in patients with mild-moderate disease, such as percent of patients experiencing late clinical recovery (23 vs 37%, $p < 0.03$)³⁹. It remains to be seen if this will be born out after peer review and in other trials. Lastly, incorporating ivermectin into COVID-19 treatment could have the added benefit of preventing *Strongyloides* hyperinfection in patients treated with dexamethasone.⁴⁰ As *Strongyloides stercoralis* is hyper-endemic in many LMICs, this could significantly reduce morbidity.

Nitazoxanide

While not on the WHO List of Essential Medicines, the antiparasitic nitazoxanide has a long history of safety and tolerability since its discovery 30 years ago. It has been investigated as an antiviral previously against MERS in 2016⁴¹, as well as influenza, with variable results^{42, 43}. Against SARS-CoV-2, nitazoxanide has a promising ratio of plasma concentration to IC50 for SARS-CoV-2 of 14:1 with standard dosing and could be produced for at a daily cost of \$0.10⁴⁴. As of January 14, 2021, while 24 clinical trials of nitazoxanide are listed on clinicaltrials.gov, only three have been completed. Notably, the SARITA-2 trial in Brazil, which showed no difference in symptoms at 5 days but did decrease viral load with no serious adverse events noted⁴⁵.

Camostat, Nafamostat, and Bromohexine

Camostat and the closely related nafamostat are serine protease inhibitors with decades of clinical use in disseminated intravascular coagulation and pancreatitis, and are well-tolerated⁴⁶. Unlike other agents for SARS-CoV-2, they act at on a human target rather than a viral target called transmembrane serine protease 2 (TMPRSS2)⁴⁷. As this is a necessary agent in the viral spike protein's function, these agents can partially inhibit SARS-CoV-2 entry into lung epithelial cells. This may be true of other viral infections as well, as an attenuated course of H1N1 influenza was noted in *Tmprss2* knockout mice. While both agents show promising *in vitro* data, nafamostat inhibited SARS-CoV-2 S-mediated entry into host cells with approximately 15-fold-higher efficiency than camostat at a low EC50⁴⁸. However, due to the requirement for intravenous administration, nafamostat has been overshadowed by oral camostat in ongoing clinical trials. Lastly, the mucolytic bromohexine, which also inhibits TMPRSS2 protease, was found ineffective in a small (n=18) randomized trial.^{49, 50}

Niclosamide

Niclosamide is another antiparasitic with a well-established safety profile that is currently on the WHO Model List of Essential Medicines⁵¹. Although it is used primarily for treatment of cestode infections, niclosamide has been found to have a low IC50 against SARS-CoV-2. Possible mechanistic

explanations for this include blocking endocytosis, inhibition of viral replication, and inhibiting receptor mediated endocytosis⁵². Despite its potential, clinical trials of this agent are very limited.

Umifenovir

Originally licensed in Russia in 1993 for treatment and prophylaxis of Influenza, umifenovir was found to inhibit SARS-CoV reproduction *in vitro* and clinical trials were quickly undertaken. A retrospective review of 81 hospitalized, non-intensive care unit patients with COVID-19 in China showed no significant differences in outcomes other than longer hospital stays in the umifenovir group⁵³. More recently, a meta-analysis of 12 studies, both retrospective and prospective, including a total of 1052 patients, found only a slightly higher rate of PCR-negative testing on hospital day 14 (CI: 1.04 to 1.55)⁵⁴. Given that the end points of the included studies were predominantly symptomatic and laboratory-based with some composite end point, no mortality comparison was made.

Daclatasvir/sofosbuvir and Ledipasvir/Sofosbuvir

The combination of sofosbuvir and either daclatasvir or ledipasvir has been used to treat hepatitis C and has proven effective for that indication and was well tolerated⁵⁵. More recently, *in silico* studies have been carried out identifying both sofosbuvir and daclatasvir as potential inhibitors of SARS-CoV-2^{56, 57, 58}. This combination offer well-established safety and tolerability as combination therapy and has been shown to be safe in patients with renal impairment²⁵. Three small trials, sometimes in combination with ribavirin, have been published. All three demonstrated reduced mortality in the treatment group, one achieving statistical significance ($p=0.02$)^{59, 60, 61}.

Molnupiravir (formerly MK-4482 and EIDD-2801)

Molnupiravir is an orally bioavailable prodrug of beta-D-N4-hydroxycytidine (NHC) that has demonstrated antiviral activity against Venezuelan Equine Encephalitis Virus⁶². More recently, it has

shown *in vitro* activity against SARS-CoV-2 with low IC50s⁶³. When testing for cytotoxicity to establish an estimated therapeutic window, NHC did not cause significant mutagenesis at concentrations as high as 100 µM. Even using the higher IC50 range, this yields a favorable SI of >300⁶³. Lastly, oral molnupiravir improved lung function in mice infected with MERS-CoV. Currently, it is in phase 2 trials in inpatient and outpatient settings⁶⁴.

Bemcentinib

Axl is one of a group of tyrosine kinase receptors which has previously been shown to mediate the entry of Zika virus⁶⁵. More recently, an *in silico* screening of approximately 9000 United States Food and Drug Administration (FDA) approved drugs for their potential to interfere with the ability of SARS-CoV-2 to evade innate immune recognition identified the Axl kinase inhibitor bemcentinib as a promising candidate⁶⁶. Moreover, bemcentinib may prevent downregulation of the innate immune response, including IFN production. Lastly, it may inhibit viral cell entry as with Zika virus and others, such as West Nile virus and Ebola virus. Bemcentinib was moved rapidly into the United Kingdom's ACcelerating COVID-19 dRUG Development (ACCORD) trial and robust clinical data are anticipated.

Fingolimod and opaganib

The role of modulating Sphingosine 1 phosphate (S1P) pathway either by enhancing or suppressing it is a controversial and sometimes contradictory in terms of the treatment of COVID-19. S1P analogues are being used as part of immune therapy with patients with multiple relapsing multiple sclerosis. Fingolimod is an oral agent that, once phosphorylated, acts as an analogue on S1PR receptors. S1P and its receptor S1P control T cell egress from the thymus and secondary lymphoid organs (SLO) as well. By activating one subtype the S1P receptor (mainly subtype I), naïve and central memory T cells are retained in SLO thus inducing lymphocytopenia⁶⁷. This was proven to be beneficial for patient with autoimmune disease mainly multiple sclerosis where it was proven to

reduce relapse rates in clinical trials⁶⁸. The proposed mechanism of the beneficial effect is that Fingolimod traps newly generated encephalitogenic T cells in lymph nodes and prevents migration to the CNS⁶⁹. Even though the physiologic response to viral infections involves lymphocyte migration, Fingolimod does not seem to affect memory B cells and its effect only targets native and central B cells, thus still allowing key immune system responses during therapy. This was proven by several infection models that showed Fingolimod therapy did not affect virus-specific cytotoxic T cells generation⁷⁰. Initial interest to S1P blockade for COVID-19 treatment sprung when several case reports for patients on Fingolimod therapy were diagnosed with COVID-19 and all had very good outcomes^{71, 72}. Given that COVID-19-induced 'cytokine storm' is a central feature of severe COVID-19, immunomodulatory therapy such as Fingolimod became a subject of interest. Acute lung injury and pulmonary edema which have been extensively described in severe COVID-19 patients are characterized by an increased in vascular permeability. S1P was proven to be a potent angiogenic factor that enhances lung cell wall integrity and an inhibitor of vascular permeability and alveolar flooding in pre-clinical models of acute lung injury⁷³. Given that Fingolimod is a S1P analogue, it has been postulated that Fingolimod might also decrease COVID-19-associated increased vascular permeability and associated lung injury⁷⁴. One phase 2 trial was planned to investigate the role of Fingolimod in COVID-19 patients but was later withdrawn. Another point to note is the unclear effect of Fingolimod-induced lymphopenia would have on COVID-19 patients given that lymphopenia is associated with worse outcomes in COVID-19 patients⁷⁵. We could not identify any other trials investigating Fingolimod in COVID-19 patients.

Opaganib is another oral agent that modulates the S1P pathway by inhibiting the enzyme sphingosine kinase isoenzyme 2 ShpK2 thus decreasing levels of S1P. S1P has been shown to be secreted by platelets, monocytes and mast cells in response to inflammation thus promoting inflammatory cascades at the site of injury^{76, 77}. In addition, S1P mimics TNF-alpha effect in increasing the expression of cyclooxygenase 2 enzyme and prostaglandin E2⁷⁸. Thus blocking S1P may provide anti-inflammatory properties. That was demonstrated in rodent models of arthritis⁷⁹.

Genetic deletion of SPHK2 in mice models conferred protection against *Pseudomonas aeruginosa* mediated lung inflammation⁸⁰. Although no in-vitro evaluation of antiviral activity of opaganib against the SARS CoV2 virus have been published, there has been previous publications demonstrating antiviral effects of targeting the SphK2 enzyme against the Chikungunya virus⁸¹, Influenza viruses⁸². Based on the postulated anti-inflammatory and antiviral properties, Opaganib was used on the basis of compassionate use in Israel in 7 patients with reported improvement in both clinical and laboratory parameters⁸³. Two trials have since then assessed the role of Opaganib. A phase 2 trial enrolled 40 patients in the US, but was not powered for statistical significance and was focused on efficacy defined by reduction in total oxygen requirement over the course of treatment up to 14 days (NCT04414618). Another global phase 2/3 trial of Opaganib in patients with severe COVID-19 pneumonia (NCT04467840) is currently enrolling patients.

Maraviroc

Computational bioinformatics have identified chemokine receptor antagonist maraviroc (MRV) as a potential antagonist to the SARS CoV2 main protease M^{pro}, 3CL^{pro}, the function of which is regulating replication and transcription by cleaving polyproteins to generate non-structural proteins (NSPs). From a replicase-transcriptase complex. Maraviroc was found to bind to the substrate-binding pocket of M^{pro} forming a significant number of non-covalent interactions⁸⁴. This has not been substantiated with in vitro studies as MRV had EC₅₀ values above 40 µM (compared with Remdesivir EC₅₀ of 1.1)⁸⁵ thus making MRV an unattractive agent clinically. Nevertheless given the pressing needs created by the pandemic, 3 trials were initiated to investigate the potential benefit of maraviroc for the treatment of COVID-19 patients: 2 are currently recruiting in Barcelona Spain⁸⁶ and Rhode Island Providence Hospital USA⁷⁸. A third trial in Mexico City has maraviroc alone or maraviroc in addition to favipiravir as treatment arms is not yet recruiting.

Doxycycline

Doxycycline is another potentially repurposed drugs to treat COVID-19 given its antiviral and anti-inflammatory properties. It has showed in vitro activity against SARS-CoV2 infected Vero E cells with median effective concentration EC50 comparable with oral and parenteral formulation⁸⁷ and has been shown to exhibit antiviral activity against several RNA viruses like dengue virus. The proposed antiviral effect mechanism may be due to upregulation of the intracellular zinc finger antiviral protein which in turns binds to specific viral mRNAs and represses RNA translation, an effect previously demonstrated with Ebola, HIV, Zika and Influenza A viruses^{88, 89}. In addition, doxycycline has been shown to stimulate pro-inflammatory cytokines including interleukin-6 and tumor necrosis factor-alpha⁹⁰ and could inhibit SARS CoV2 papain-like protease^{91, 92}. The Oxford Platform Randomised trial of Interventions against COVID-19 In older peoPLE (PRINCIPLE) which targeted adults with COVID-19 in the outpatient includes an arm for usual care plus doxycycline. In another small scale trial, ivermectin/doxycycline combination vs standard of care was shown to reduce time to recovery and disease progression⁹³.

JAK/STAT inhibitors

In an attempt to mitigate the hyper inflammatory cytokine storm associated with COVID-19, JAK/STAT inhibitors ruxolitinib and baricitinib were both investigated as potential therapeutics. Both inhibit the intracellular pathways of cytokines known to be elevated in severe COVID-19. Baricitinib was also identified as a numb-associated kinase²⁵, with a particularly high affinity for AP-2 associated protein Kinase-1, an important regulator of clathrin-mediated viral endocytosis, and thus could potentially inhibit intracellular viral replication^{94, 95}. Several cases series have demonstrated a beneficial effect of baricitinib in treatment of COVID-19 patients^{96, 97}. The International Society for Influenza and other Respiratory Virus Disease Antiviral Group Conference reported that the addition of baricitinib to remdesivir in patients hospitalized with COVID-19 was associated with shorter hospital stay (8 vs 7 days, p=0.04) and that there was a decrease in death, though not achieving statistical significance, for death at 29 days in the baricitinib group (5.1 vs 7.8%, p=0.09)⁹⁸. The ACTT-

2 trial (Adaptive COVID-19 Treatment Trial-2) was a multinational, multicenter placebo-controlled double randomized trial that demonstrated the combination therapy of remdesivir and baricitinib vs remdesivir alone provided a lower time to recovery in patients requiring high-flow oxygen⁹. Another JAK1/2 inhibitor, ruxolitinib, was studied in a small randomized trial in Wuhan, China, patients treated with ruxolitinib did not have statistically significant reductions in time to clinical improvement nor survival³². An unpublished Phase III multicenter, randomized, double blind placebo-controlled trial comparing ruxolitinib with standards of care (RUXCOVID) failed to meet its primary endpoint of severe complications⁹⁹.

Discussion

This review of candidate COVID-19 therapeutics highlights some of the extensive work already completed in screening individual compounds. It should be noted that the therapeutics arm of the Access to COVID-19 Tools Accelerator, with funding from the Bill and Melinda Gates Foundation, the Wellcome Trust, the Mastercard Impact Fund, National Institutes of Health, and others, have worked to advance this agenda substantially, coordinating the sharing of preclinical compound libraries and clinical research^{100, 101}. Another example of such work is the 'Accelerating COVID-19 Therapeutic Interventions and Vaccines' or 'ACTIV' public-private consortium, involving United States' government agencies, the European Medicines Agency, and private industry¹⁰². More critical work remains to be added to the achievements of this team and others toward the design and implementation of adaptive, pragmatic clinical trials specifically targeted for the resource-constrained settings of LMICs. Of note, given the lessons learned from treatments for other viruses such as HIV and hepatitis C virus, it is possible that combination therapy could prove more beneficial than monotherapy alone. The following framework, adapted from other proposed frameworks¹⁰³, has an emphasis on rapid discovery of agents for LMICs. It highlights the aim of advancing candidate agents from pre-clinical screening of compounds to clinical trials, with an intentional focus on the unmet needs in LMICs (fig 2).

406

407 Using a library of known compounds has the benefit not only of rapid development and
408 established drug safety profiles, but also higher likelihood of avoiding licensing costs, making
409 delivery to LMICs both more rapid and less costly to facilitate widespread access. Initial identification
410 of known candidate agents for treatment of COVID-19 has mostly been achieved with computer
411 modeling, or *in silico* testing¹⁰⁴. Notable achievements on this front include protein interaction
412 mapping¹⁰⁵, which yielded both clinical and pre-clinical candidate agents as well as the screening of
413 agents with established human safety profiles such as the ReFRAME library. This catalog of over
414 12,000 compounds has already been used to identify candidates for treatment of other infectious
415 diseases such as tuberculosis and cryptosporidiosis¹⁰⁶. Using this technique, Riva *et al.* reported the
416 identification of new COVID-19 candidate agents such as apilimod¹⁰⁷.

417

418 While screening of individual agents has progressed rapidly, screening for combination
419 therapy or “cocktails” has been less robust, particularly when excluding trials using combinations
420 including HCQ. While no agents may be highly effective alone, combinations of various agents may
421 prove efficacious, as can be seen in HIV and hepatitis C^{108, 109}. In these cases, preventing resistance to
422 therapy through mutations is an important driver of combination therapy. Another rationale for
423 combination therapy is targeting multiple points in regulatory circuits, which are often redundant to
424 help maintain homeostasis. Well-designed pre-clinical studies with such targets in mind can help
425 yield effective combination therapies¹¹⁰. Lastly, combination therapy, specifically using drug
426 repurposing, has been a demonstrated means to address urgent needs for drugs in infectious
427 disease when research lags behind clinical need¹¹¹.

428

429 One early example of screening for combination therapies, though in preprint as of 20
430 November 2020, identified 16 synergistic combinations, but also 8 antagonistic combinations¹¹². For
431 example, synergy was found between nitazoxanide and several other compounds, and strong

antagonism was found *in vitro* with the combination of remdesivir and hydroxychloroquine. While some clinical trials of “cocktail” therapy for COVID-19 are underway (interferon beta-1a with remdesivir, nitazoxanide with atazanavir, and nitazoxanide with ivermectin to name a few), *a priori* screening for candidate COVID-19 therapeutic combinations *in silico* followed by *in vitro* synergy studies could lead more rapidly to clinical trials of effective treatment of COVID-19 in LMICs and elsewhere. However, the complexities associated manufacturing and administration of combination therapies should be considered, and those with potential for affordability and availability in LMICs can be prioritized.

Despite a large number of ongoing clinical trials worldwide, only a small portion of these are adequately powered, randomized double-blinded placebo controlled clinical trials. Moreover, an even smaller fraction are currently being conducted in LMICs, likely due to several barriers. First, large clinical trials in LMICs are often require highly collaborative international partnerships. In-person site visits and collaboration, often integral to such work, has been curtailed in an effort to control the very pandemic they would seek to address. Second, diagnostic resources and capacity are more limited in LMICs compared to many higher-income countries. This limitation of available and accurate testing in LMICs could pose a threefold challenge: impeding modeling of the spread of the pandemic to facilitate well-planned trials, reducing identification and recruitment of proven cases, and further limiting diagnostic capacity for direct research use. Lastly, these interventions require trial expertise in multiple clinical settings: as treatment of severe, hospitalizing disease to reduce morbidity and mortality, as treatment of mild or moderate disease to reduce progression and transmission of disease, and as prophylactic or presumptive treatment. Indeed, targeted prophylaxis or presumptive treatment to high risk groups may be one of the more promising roles for such agents, with examples of success in LMICs with meningococcal disease¹¹³ and malaria¹¹⁴.

Though these challenges are significant, they are not insurmountable. New drug candidates appear rapidly and a coordinated adaptive trial design should be used. As the clinical context of this disease is global, focused clinical endpoints that do not require extensive resources can provide rigor without burdening researchers with added cost and complexity. Designing such trials requires broad expertise and thus broad collaboration. Such trial protocols can be then distributed, decreasing burdens on aspiring trialists and increasing sample sizes and sites, and thus improving power and generalizability of findings. Indeed, some or all of the above approaches have been used by groups such as RECOVERY, SOLIDARITY, and ACTT1-3, to name a few. These trials have provided some of the most actionable results to date, with positive and negative results. An example of work to coordinate such large efforts with open collaboration is the COVID-19 Clinical Research Coalition, which has called for and facilitated large RCTs in LMIC and has made research materials available for these studies⁸⁶. Many of the agents in these trials, such as hydroxychloroquine, are now of lower interest given repeated negative findings. However, this framework of collaboration, in combination with the screening techniques discussed above, could lead more rapidly to much-needed therapies.

Conclusions

Particularly for LMICs, injectable tools against COVID-19 - whether vaccines, or therapeutics such as remdesivir and monoclonal antibodies which are not included in this review - present challenges in production, distribution, and uptake. Agents that are accessible and easily administered, as well as combinations of such agents, can and should be emphasized in pragmatic, adaptive clinical trials specifically targeted for LMICs. Such efforts could yield not only more rapid results but also a truly global impact whereby we can prevent COVID-19 from becoming a neglected tropical disease.

Acknowledgements

We thank Richard Feachem and Kathryn Vosburg from the Pandemic Response Initiative, Institute for Global Health Sciences, University of California, UCSF, for their guidance on and review of the manuscript.

Figure legends

Figure 1. Flow diagram for trial search in World Health Organization International Clinical Trials Registry Platform (WHO ICTRP)

Figure 2. Proposed workflow for identifying effective COVID-19 therapeutics

Funding

This work was supported by funding from the Lampert Byrd Foundation.

Table 1. COVID-19 candidate therapeutics with highest potential to be available and easily administrable in the near future

Candidate therapeutic	Therapeutic Class	Examples of current uses	Rationale / Mechanism of action ⁹⁷	Limitations / Potential obstacles	Trials in United States National Library of Medicine (NLM) clinicaltrials.gov		Trials in European Union Clinical Trials Register clinicaltrialsregister.eu		Trials in WHO (World Health Organization) International Clinical Trials Registry Platform (ICTRP) list	
					Listed	Completed	Listed	Completed	Listed	Phase 4
Hydroxychloroquine ^{11, 12, 13, 14, 15, 16, 17, 115}	Antimalarial	Malaria, autoimmune conditions, rheumatologic diseases	Block viral entry by impairing terminal glycosylation of ACE2 receptors, proteolytic processing, and endosomal acidification; immunomodulator	Multiple negative trials in all phases of illness, from pre-exposure prophylaxis to treatment of hospitalized patients	231	37	70	2	376	32
Azithromycin ^{18, 19, 20, 21, 22, 23, 24}	Macrolide antibiotic	Community-acquired pneumonia	Alkalinization of endosomal vesicles / lysosomes, potentially inhibiting endocytosis and/or uncoating of enveloped viruses.	No RCTs completed to date except with HCQ/CQ, where it was not shown to be helpful and some signal for harm.	19	1	27	0	32	6
Interferon ^{11, 25, 26, 27, 28, 29, 30}	Biologic response modifier	Hepatitis C, multiple sclerosis	Strengthens IFN response to SARS-CoV-2 infection	Subcutaneous administration (though nasal administration possible), large negative trial	98	9	16	0	99	15
Lopinavir/ritonavir ^{11, 15, 31}	Antiviral	HIV (older regimen)	Protease inhibition	Large negative trial	73	9	20	0	134	6
Favipiravir ^{32, 33, 34, 35}	Antiviral	Investigations for Nipah virus, Ebola, and other flaviviruses	RNA-dependent RNA polymerase inhibition	Safety concerns regarding increases in blood uric acid and teratogenic potential	42	9	7	0	65	1
Ivermectin ^{36, 37, 38, 39, 40}	Antiparasitic	Onchocerciasis, lymphatic filariasis, soil-transmitted helminths, scabies	Nuclear transport inhibition	May be difficult to achieve therapeutic dose	43	12	5	0	70	1

Nitazoxanide ^{41, 42, 43, 44, 45}	Antiparasitic	Cryptosporidiosis, broad-spectrum antiparasitic	Phosphorylation of protein kinase activated by dsRNA; immunomodulator	Trials in early stages	24	3	0	0	27	0
Camostat, Nafamostat, and Bromohexine ^{47, 48}	Serine protease inhibition	Chronic pancreatitis	TMPRSS2 inhibitor	Trials pending	26	0	6	0	32	3
Baricitinib ^{98, 116, 117}	JAK1/JAK2 inhibitor	Rheumatoid arthritis	May inhibit viral entry via clathrin-dependent endocytosis; immunomodulator	IP owned by Eli Lilly	13	2	9	1	16	4
Niclosamide ⁵²	Antiparasitic	Tapeworm infections	Inhibits viral entry by change in endosomal pH; inhibit autophagy	Trials few in number and in early stages	10	0	2	0	10	2
Umifenovir ^{53, 54}	Antiviral	Influenza	Impede trimerization of spike glycoprotein; inhibits adhesion	Trials pending	10	0	0	0	4	0
Daclatasvir / Sofosbuvir and Ledipasvir/Sofosbuvir ^{25, 55, 56, 57, 58, 59, 60, 61, 118}	Antiviral	Hepatitis C	RNA polymerase inhibition	Concerns regarding partial treatment of undiagnosed hepatitis C virus	7	0	0	0	16	0
Molnupiravir (formerly MK-4482 and EIDD-2801) ^{62, 63, 64}	Antiviral	Developed for influenza, investigated for SARS, MERS	Nucleoside analogue	Early phase trials; intellectual property (IP) owned by Ridgeback, possible mutagenicity (disputed)	5	1	0	0	0	0
Bemcentinib ^{65, 66}	AXL kinase inhibition	Trials for malignancy (lung, breast, leukemia, etc)	Block viral entry; enhance IFN	IP owned by BerGenBio	0	0	1	0	2	0
Fingolimod ^{67, 68, 69, 70, 71, 72, 73, 74, 75}	S1P analogue	Relapsing multiple sclerosis	Enhancing S1P can sequester newly generated cytotoxic T cells while preserving memory T cells (immune-modulatory effect). S1P also enhances lung epithelium cell wall	One trial withdrawn	1	0	0	0	2	0

			integrity							
Opaganib ^{76, 77, 78, 79, 80, 81, 83, 119}	ShpK2 inhibitor	Investigated in solid organ tumor, multiple myeloma, and prostate cancer	Inhibiting S1P can have anti-inflammatory and antiviral effects	No solid literature backing postulated claims, no <i>in vitro</i> effect on SARS CoV2	3	0	1	0	4	0
Maraviroc ^{84, 85, 120, 121}	CCR5 antagonist	HIV	potential antagonist to the SARS CoV2 main protease Mpro, 3CL pro	MRV had EC50 values above 40 µM (compared with Remdesevir EC50 of 1.1)	3	0	1	0	3	0
Doxycycline ^{89, 90, 91, 93, 122, 123, 124, 125, 126, 127}	S30 bacterial ribosomal inhibitor	Antibiotic	-upregulation of the intracellular zinc finger antiviral protein - an anti-inflammatory profile -could inhibit SARS CoV2 papain-like protease		12	4	1	0	15	2
Ruxolitinib ^{94, 95, 96, 97, 128, 129, 130, 131}	JAK1/2 Kinase inhibitor	Used for MF, RA	Potentially inhibits AAK-1, NAK and prevents clathrin-mediated viral endocytosis. Anti-inflammatory agent for cytokine storm	Not as potent AAK1 inhibitor as baricitinib	16	1	9	1	23	0
Totals					636	88	175	4	930	72

Co-author contact information

Daniel Maxwell, UT Southwestern Medical Center, Daniel.Maxwell@UTSouthwestern.edu

Kelly C. Sanders, University of California, San Francisco (UCSF), Kelly.Sanders@ucsf.edu

Oliver Sabot, UCSF, ojsabot15@gmail.com

Ahmad Hachem, UT Southwestern Medical Center, Ahmad.Hachem@UTSouthwestern.edu

Alejandro Llanos-Cuentas, Universidad Peruana Cayetano Heredia (UPCH),

alejandro.llanos.c@upch.pe

Ally Olotu, Ifakara Health Institute, aolotu@ihi.or.tz

Roly Gosling, UCSF, roly.gosling@ucsf.edu

James B. Cutrell, UT Southwestern Medical Center, James.Cutrell@UTSouthwestern.edu

References

1. Alwan NA, Burgess RA, Ashworth S, Beale R, Bhadelia N, Bogaert D, Dowd J, Eckerle I, Goldman LR, Greenhalgh T, 2020. Scientific consensus on the COVID-19 pandemic: we need to act now. *The Lancet* 396: e71-e72.
2. Shuchman M, 2020. Low- and middle-income countries face up to COVID-19. Available at: <https://www.nature.com/articles/d41591-020-00020-2>. Accessed 27 Oct, 2020.
3. United Nations Development Programme, 2020. COVID-19 and health system vulnerabilities in the poorest developing countries. Available at: https://www.undp.org/content/dam/undp/library/km-gap/Transitions%20Series/undp-gpn-transitions-series-health-COVID-19_and_Health_System_Vulnerabilities_EN.pdf. Accessed Nov 22, 2020.
4. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S, 2020. The COVID-19 vaccine development landscape. *Nature Reviews Drug Discovery* 19: 305-306.
5. Peeples L, 2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. *Proceedings of the National Academy of Sciences* 117: 8218-8221.
6. Hoest C, Seidman JC, Lee G, Platts-Mills JA, Ali A, Olortegui MP, Bessong P, Chandyo R, Babji S, Mohan VR, Mondal D, Mahfuz M, Mduma ER, Nyathi E, Abreu C, Miller MA, Pan W, Mason CJ, Knobler SL, 2017. Vaccine coverage and adherence to EPI schedules in eight resource poor settings in the MAL-ED cohort study. *Vaccine* 35: 443-451.
7. Thielmann A, Puth M-T, Kersting C, Porz J, Weltermann B, 2019. Vaccine cold chain in general practices: A prospective study in 75 refrigerators (Keep Cool study). *PLOS ONE* 14: e0224972.
8. Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK, 2020. Ensuring global access to COVID-19 vaccines. *The Lancet* 395: 1405-1406.
9. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez De Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M-D, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, 2020. Remdesivir for the Treatment of Covid-19 — Preliminary Report. *New England Journal of Medicine*.
10. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D, 2020. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 71: 732-739.
11. WHO Solidarity Trial Consortium, 2020. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. medRxiv doi: 10.1101/2020.10.15.20209817v1.
12. 2020. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *New England Journal of Medicine*.
13. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hullsiek KH, Cheng MP, Luke D, Lothar SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR, 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. *Annals of Internal Medicine*.
14. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, Labar D, Lothar SA, Mackenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH, 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *New England Journal of Medicine*.

15. RECOVERY Collaborative Group, Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, Palfreeman A, Raw J, Elmahi E, Prudon B, Green C, Carley S, Chadwick D, Davies M, Wise MP, Baillie JK, Chappell LC, Faust SN, Jaki T, Jefferey K, Lim WS, Montgomery A, Rowan K, Juszczak E, Haynes R, Landray MJ, 2020. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet*.
16. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, Hensley SE, Gill S, Vogl DT, Maillard I, Babushok DV, Huang AC, Nasta SD, Walsh JC, Wiletyo EP, Gimotty PA, Milone MC, Amaravadi RK, Prevention at, Investigators ToC-WH, 2020. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Internal Medicine*.
17. Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, Pullen MF, Nascene AA, Williams DA, Engen NW, Okafor EC, Rini BI, Mayer IA, McDonald EG, Lee TC, Li P, Mackenzie LJ, Balko JM, Dunlop SJ, Hullsiek KH, Boulware DR, Lofgren SM, 2020. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. *Clinical Infectious Diseases*.
18. Damle B, Vourvahis M, Wang E, Leaney J, Corrigan B, 2020. Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. *Clinical Pharmacology & Therapeutics* 108: 201-211.
19. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, Damiani LP, Marcadenti A, Kawano-Dourado L, Lisboa T, Junqueira DLM, De Barros E Silva PGM, Tramuja L, Abreu-Silva EO, Laranjeira LN, Soares AT, Echenique LS, Pereira AJ, Freitas FGR, Gebara OCE, Dantas VCS, Furtado RHM, Milan EP, Golin NA, Cardoso FF, Maia IS, Hoffmann Filho CR, Kormann APM, Amazonas RB, Bocchi De Oliveira MF, Serpa-Neto A, Falavigna M, Lopes RD, Machado FR, Berwanger O, 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *New England Journal of Medicine* 383: 2041-2052.
20. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, Zampieri FG, Veiga VC, Azevedo LCP, Rosa RG, Lopes RD, Avezum A, Manoel ALO, Piza FMT, Martins PA, Lisboa TC, Pereira AJ, Olivato GB, Dantas VCS, Milan EP, Gebara OCE, Amazonas RB, Oliveira MB, Soares RVP, Moia DDF, Piano LPA, Castilho K, Momesso RGRAP, Schettino GPP, Rizzo LV, Neto AS, Machado FR, Cavalcanti AB, 2020. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *The Lancet* 396: 959-967.
21. Kim MS, An MH, Kim WJ, Hwang T-H, 2020. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. *PLOS Medicine* 17: e1003501.
22. Oldenburg CE, Doan T, 2020. Azithromycin for severe COVID-19. *The Lancet* 396: 936-937.
23. Doan T, Hinterwirth A, Arzika AM, Worden L, Chen C, Zhong L, Oldenburg CE, Keenan JD, Lietman TM, 2020. Reduction of Coronavirus Burden With Mass Azithromycin Distribution. *Clinical Infectious Diseases* 71: 2282-2284.
24. Hinks TSC, Barber VS, Black J, Dutton SJ, Jabeen M, Melhorn J, Rahman NM, Richards D, Lasserson D, Pavord ID, Bafadhel M, 2020. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. *Trials* 21.
25. Poustchi H, Majd Jabbari S, Merat S, Sharifi AH, Shayesteh AA, Shayesteh E, Minakari M, Fattahi MR, Moini M, Roozbeh F, Mansour-Ghanaei F, Afshar B, Mokhtare M, Amirani T, Sofian M, Somi MH, Agah S, Maleki I, Latifnia M, Fattahi Abdizadeh M, Hormati A, Khoshnia M, Sohrabi M, Malekzadeh Z, Merat D, Malekzadeh R, 2020. The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. *J Gastroenterol Hepatol*.

26. Gao L, Yu S, Chen Q, Duan Z, Zhou J, Mao C, Yu D, Zhu W, Nie J, Hou Y, 2010. A randomized controlled trial of low-dose recombinant human interferons α -2b nasal spray to prevent acute viral respiratory infections in military recruits. *Vaccine* 28: 4445-4451.
27. Jiang H-w, Zhang H-n, Meng Q-f, Xie J, Li Y, Chen H, Zheng Y-x, Wang X-n, Qi H, Zhang J, Wang P-H, Han Z-G, Tao S-c, 2020. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. *Cellular & Molecular Immunology* 17: 998-1000.
28. Clementi N, Ferrarese R, Criscuolo E, Diotti RA, Castelli M, Scagnolari C, Burioni R, Antonelli G, Clementi M, Mancini N, 2020. Interferon- β -1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection. *The Journal of Infectious Diseases*.
29. Hung IF-N, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, Ng Y-Y, Lo J, Chan J, Tam AR, Shum H-P, Chan V, Wu AK-L, Sin K-M, Leung W-S, Law W-L, Lung DC, Sin S, Yeung P, Yip CC-Y, Zhang RR, Fung AY-F, Yan EY-W, Leung K-H, Ip JD, Chu AW-H, Chan W-M, Ng AC-K, Lee R, Fung K, Yeung A, Wu T-C, Chan JW-M, Yan W-W, Chan W-M, Chan JF-W, Lie AK-W, Tsang OT-Y, Cheng VC-C, Que T-L, Lau C-S, Chan K-H, To KK-W, Yuen K-Y, 2020. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* 395: 1695-1704.
30. Davoudi-Monfared E, Rahmani H, Khalili H, Hajiabdolbaghi M, Salehi M, Abbasian L, Kazemzadeh H, Yekaninejad MS, 2020. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β -1a in Treatment of Severe COVID-19. *Antimicrobial Agents and Chemotherapy* 64.
31. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C, 2020. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* 382: 1787-1799.
32. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L, 2020. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. *Engineering*.
33. Coomes EA, Haghbayan H, 2020. Favipiravir, an antiviral for COVID-19? *Journal of Antimicrobial Chemotherapy* 75: 2013-2014.
34. Smith SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS, 2014. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. *Antiviral Res* 104: 153-5.
35. Glenmark Pharmaceuticals L, 2020. Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19. Phase 3 Trial Demonstrates Statistically Significant Faster Time to Clinical Improvement with Favipiravir Treatment in Mild to Moderate COVID 19 Patients Compared to Control.
36. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM, 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Research* 178: 104787.
37. Schmith VD, Zhou J, Lohmer LRL, 2020. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. *Clinical Pharmacology & Therapeutics*.
38. Konecny P, Weatherall CJ, Adhikari S, Duflou J, Marjoniemi V, Pretorius CJ, McWhinney B, 2018. Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis. *The American journal of tropical medicine and hygiene* 99: 1580-1582.

39. Mahmud R, 2020. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection. Available at: <https://clinicaltrials.gov/ct2/show/NCT04523831>. Accessed 22 Oct, 2020.
40. Stauffer WM, Alpern JD, Walker PF, 2020. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection. JAMA.
41. Rossignol J-F, 2016. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. Journal of Infection and Public Health 9: 227-230.
42. Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol J-F, 2014. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. The Lancet Infectious Diseases 14: 609-618.
43. Gamiño-Arroyo AE, Guerrero ML, McCarthy S, Ramírez-Venegas A, Llamosas-Gallardo B, Galindo-Fraga A, Moreno-Espinosa S, Roldán-Aragón Y, Araujo-Meléndez J, Hunsberger S, Ibarra-González V, Martínez-López J, García-Andrade LA, Kapushoc H, Holley HP, Smolskis MC, Ruiz-Palacios GM, Beigel JH, Mexico Emerging Infectious Diseases Clinical Research N, 2019. Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness. Clinical Infectious Diseases 69: 1903-1911.
44. Pepperrell T, Pilkington V, Owen A, Wang J, Hill AM, 2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of virus eradication 6: 52-60.
45. Rocco PRM SP, Cruz FF, 2020. Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial. medRxiv.
46. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB, 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). JAMA.
47. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW, 2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discovery 10: 779-782.
48. Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S, 2020. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrobial Agents and Chemotherapy.
49. Li T, Sun L, Zhang W, Zheng C, Jiang C, Chen M, Chen D, Dai Z, Bao S, Shen X, 2020. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study. Clin Transl Sci 13: 1096-1102.
50. Maggio R, Corsini GU, 2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res 157: 104837.
51. WHO, 2019. The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children).
52. Pindiprolu SKSS, Pindiprolu SH, 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19. Medical Hypotheses 140: 109765.
53. Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q, 2020. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clinical Microbiology and Infection 26: 917-921.
54. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z, 2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Journal of Medical Virology.
55. Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki JP, Ledinghen VD, Zoulim F, Tran A, Metivier S, Zarski JP, Samuel D, Guyader D, Marcellin P, Minello A, Alric L, Thabut D, Chazouilleres O, Riachi G, Bourcier V, Mathurin P, Loustaud-Ratti V, D'Alteroche L, Fouchard-Hubert I, Habersetzer F, Causse X, Geist C, Rosa I, Gournay J, Saillard E, Billaud E,

- Petrov-Sanchez V, Diallo A, Fontaine H, Carrat F, 2017. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. *J Hepatol* 66: 39-47.
56. Ahmed S, Mahtarin R, Ahmed SS, Akter S, Islam MS, Mamun AA, Islam R, Hossain MN, Ali MA, Sultana MUC, Parves MR, Ullah MO, Halim MA, 2020. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2. *J Biomol Struct Dyn*: 1-16.
57. Shah B, Modi P, Sagar SR, 2020. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. *Life sciences* 252: 117652-117652.
58. Elfiky AA, 2020. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. *Life Sciences* 253: 117592.
59. Abbaspour Kasgari H, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi AR, Davoudi L, Alikhani A, Hedayatizadeh Omran A, Saeedi M, Merat S, Wentzel H, Garratt A, Levi J, Simmons B, Hill A, Tirgar Fakheri H, 2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. *J Antimicrob Chemother* 75: 3373-3378.
60. Eslami G, Mousaviasl S, Radmanesh E, Jelvey S, Bitaraf S, Simmons B, Wentzel H, Hill A, Sadeghi A, Freeman J, Salmanzadeh S, Esmaeilian H, Mobarak M, Tabibi R, Jafari Kashi AH, Lotfi Z, Talebzadeh SM, Wickramatillake A, Momtazan M, Hajizadeh Farsani M, Marjani S, Mobarak S, 2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. *J Antimicrob Chemother* 75: 3366-3372.
61. Sadeghi A, Ali Asgari A, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, Hosamirudsai H, Afhami S, Akbarpour E, Aliannejad R, Radmard AR, Davarpanah AH, Levi J, Wentzel H, Qavi A, Garratt A, Simmons B, Hill A, Merat S, 2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. *J Antimicrob Chemother* 75: 3379-3385.
62. Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I, 2018. β -d-N (4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. *J Virol* 92.
63. Sheahan TP, Sims AC, Zhou S, Graham RL, Pruijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinno KH, 3rd, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS, 2020. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Sci Transl Med* 12.
64. Slaoui M, Greene SE, Woodcock J, 2020. Bridging the Gap at Warp Speed — Delivering Options for Preventing and Treating Covid-19. *New England Journal of Medicine*.
65. Meertens L, Labeau A, Dejarnac O, Cipriani S, Sinigaglia L, Bonnet-Madin L, Le Charpentier T, Hafirassou ML, Zamborlini A, Cao-Lormeau V-M, Culpier M, Missé D, Jouvenet N, Tabibiazar R, Gressens P, Schwartz O, Amara A, 2017. Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses. *Cell Reports* 18: 324-333.
66. Encinar JA, Menendez JA, 2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. *Viruses* 12: 525.
67. Halin C, Scimone ML, Bonasio R, Gauguier J-M, Mempel TR, Quackenbush E, Proia RL, Mandala S, von Andrian UH, 2005. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. *Blood* 106: 1314-1322.

68. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *New England Journal of Medicine* 362: 387-401.
69. Massberg S, von Andrian UH, 2006. Fingolimod and sphingosine-1-phosphate—modifiers of lymphocyte migration. *New England Journal of Medicine* 355: 1088-1091.
70. Pinschewer DD, Brinkmann V, Merkler D, 2011. Impact of sphingosine 1-phosphate modulation on immune outcomes. *Neurology* 76: S15-S19.
71. Valencia-Sanchez C, Wingerchuk DM, 2020. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19. *Multiple Sclerosis and Related Disorders*: 102182.
72. Foerch C, Friedauer L, Bauer B, Wolf T, Adam EH, 2020. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. *Multiple Sclerosis and Related Disorders*: 102180.
73. Natarajan V, Dudek SM, Jacobson JR, Moreno-Vinasco L, Huang LS, Abassi T, Mathew B, Zhao Y, Wang L, Bittman R, 2013. Sphingosine-1-phosphate, FTY720, and Sphingosine-1-phosphate receptors in the pathobiology of acute lung injury. *American journal of respiratory cell and molecular biology* 49: 6-17.
74. Lisi L, Lacal PM, Barbaccia ML, Graziani G, 2020. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. *Biochemical pharmacology*: 114169.
75. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MM, Dahly DL, Damen JA, Debray TP, 2020. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *bmj* 369.
76. Yatomi Y, Ruan F, Hakomori S-i, Igarashi Y, 1995. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets.
77. Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T, 1999. The Balance between Sphingosine and Sphingosine-1-Phosphate Is Decisive for Mast Cell Activation after Fcε Receptor I Triggering. *The Journal of experimental medicine* 190: 1-8.
78. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM, Hannun YA, 2003. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-α. *The FASEB Journal* 17: 1411-1421.
79. Maines LW, Fitzpatrick LR, French KJ, Zhuang Y, Xia Z, Keller SN, Upson JJ, Smith CD, 2008. Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. *Digestive diseases and sciences* 53: 997-1012.
80. Ebenezer DL, Berdyshev EV, Bronova IA, Liu Y, Tiruppathi C, Komarova Y, Benevolenskaya EV, Suryadevara V, Ha AW, Harijith A, 2019. *Pseudomonas aeruginosa* stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. *Thorax* 74: 579-591.
81. Reid SP, Tritsch SR, Kota K, Chiang C-Y, Dong L, Kenny T, Brueggemann EE, Ward MD, Cazares LH, Bavari S, 2015. Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex. *Emerging microbes & infections* 4: 1-9.
82. Cai MJ, Zhan FX, Kong XN, Zhu SZ, Cui Y, Wang Q, 2018. RING domain of zinc finger protein like 1 is essential for cell proliferation in endometrial cancer cell line RL95-2. *Gene* 677: 17-23.
83. Kurd R, Ben-Chetrit E, Karamah H, Bar-Meir M, 2020. Compassionate Use of Opaganib For Patients with Severe COVID-19. *medRxiv*.
84. Shamsi A, Mohammad T, Anwar S, AlAjmi MF, Hussain A, Rehman M, Islam A, Hassan M, 2020. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. *Bioscience Reports* 40.

85. Okamoto M, Toyama M, Baba M, 2020. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Research* 182: 104902.
86. COVID-19 Clinical Research Coalition, 2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *Lancet* 395: 1322-1325.
87. Gendrot M, Andreani J, Jardot P, Hutter S, Boxberger M, Mosnier J, Le Bideau M, Duflot I, Fonta I, Rolland C, In vitro antiviral activity of doxycycline against SARS-CoV-2.
88. Cai J, Wang X, Zhao B, Yao W, Wang X, Zhu Q, Zeng M, 2014. Prevalence, genetic drift of haemagglutinin, and antiviral resistance of influenza A/H3N2 viruses circulating in Shanghai in children during 2009-2012. *J Med Virol* 86: 1026-33.
89. Rothan HA, Mohamed Z, Paydar M, Abd Rahman N, Yusof R, 2014. Inhibitory effect of doxycycline against dengue virus replication in vitro. *Archives of virology* 159: 711-718.
90. Fredeking TM, Zavala-Castro JE, González-Martínez P, Moguel-Rodríguez W, C Sanchez E, J Foster M, A Diaz-Quijano F, 2015. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. *Recent patents on anti-infective drug discovery* 10: 51-58.
91. Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC, 2005. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. *Journal of virology* 79: 15189-15198.
92. Cai J, Liu W, Wong CW, Zhu W, Lin Y, Hu J, Xu W, Zhang J, Sander M, Wang Z, Dan J, Zhang J, Liu Y, Guo L, Qin Z, Liu X, Liu Y, Yan G, Wu S, Liang J, 2020. Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. *Oncogene* 39: 5995-6008.
93. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulmir AS, 2020. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. *medRxiv*.
94. Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richardson PJ, Monteil V, Lauschke VM, Mirazimi A, Youhanna S, 2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. *EMBO Molecular Medicine*.
95. Bekerman E, Neveu G, Shulla A, Brannan J, Pu S-Y, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, 2017. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. *The Journal of clinical investigation* 127: 1338-1352.
96. Cantini F, Niccoli L, Nannini C, Matarrese D, Di Natale ME, Lotti P, Aquilini D, Landini G, Cimolati B, Di Pietro MA, 2020. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. *Journal of Infection* 81: 647-679.
97. Titanji BK, Farley MM, Mehta A, Connor-Schuler R, Moanna A, Cribbs SK, O'Shea J, DeSilva K, Chan B, Edwards A, 2020. Use of baricitinib in patients with moderate and severe COVID-19. *Clinical Infectious Diseases*.
98. PRNewswire, Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen Available at: <https://www.prnewswire.com/news-releases/baricitinib-has-significant-effect-on-recovery-time-most-impactful-in-covid-19-patients-requiring-oxygen-301148840.html>. Accessed 23 Oct, 2020.
99. Sheahan TP, Sims AC, Zhou S, Graham RL, Puijssers AJ, Agostini ML, Leist SR, Schäfer A, Dinnon KH, Stevens LJ, Chappell JD, Lu X, Hughes TM, George AS, Hill CS, Montgomery SA, Brown AJ, Bluemling GR, Natchus MG, Saindane M, Kolykhalov AA, Painter G, Harcourt J, Tamin A, Thornburg NJ, Swanstrom R, Denison MR, Baric RS, 2020. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine* 12: eabb5883.
100. Snow RW, Korenromp EL, Gouws E, 2004. Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? *The American journal of tropical medicine and hygiene* 71: 16-24.
101. WHO, 2020. The Access to COVID-19 Tools (ACT) Accelerator. Available at: <https://www.who.int/initiatives/act-accelerator>. Accessed 19 Nov 2020, 2020.

102. United States National Institute of Health, 2020. Available at: <https://www.nih.gov/research-training/medical-research-initiatives/activ>. Accessed Nov 20, 2020.
103. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S, 2019. Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery* 18: 463-477.
104. Wang J, 2020. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study. *Journal of Chemical Information and Modeling* 60: 3277-3286.
105. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Huettenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chiorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang X-P, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu D, Wang H-Y, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, et al., 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature*.
106. Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, Love MS, Hull MV, Kuhen KL, Woods AK, Joseph SB, Petrassi HM, McNamara CW, Tremblay MS, Su AI, Schultz PG, Chatterjee AK, 2018. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. *Proceedings of the National Academy of Sciences* 115: 10750-10755.
107. Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV, Chang MW, Chan JF-W, Cao J, Poon VK-M, Herbert KM, Cheng K, Nguyen T-TH, Rubanov A, Pu Y, Nguyen C, Choi A, Rathnasinghe R, Schotsaert M, Miorin L, Dejoze M, Zwaka TP, Sit K-Y, Martinez-Sobrido L, Liu W-C, White KM, Chapman ME, Lendy EK, Glynn RJ, Albrecht R, Ruppin E, Mesecar AD, Johnson JR, Benner C, Sun R, Schultz PG, Su AI, Garcia-Sastre A, Chatterjee AK, Yuen K-Y, Chanda SK, 2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. *Nature*.
108. Maeda K, Das D, Kobayakawa T, Tamamura H, Takeuchi H, 2019. Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication. *Curr Top Med Chem* 19: 1621-1649.
109. Vilarinho S, Lifton RP, 2016. Pioneering a global cure for chronic hepatitis C virus infection. *Cell* 167: 12-15.
110. 2017. Rationalizing combination therapies. *Nature Medicine* 23: 1113-1113.
111. Phougat N, Khatri S, Singh A, Dangi M, Kumar M, Dabur R, Chhillar AK, 2014. Combination therapy: the propitious rationale for drug development. *Comb Chem High Throughput Screen* 17: 53-67.
112. Bobrowski T, Chen L, Eastman RT, Itkin Z, Shinn P, Chen C, Guo H, Zheng W, Michael S, Simeonov A, Hall MD, Zakharov AV, Muratov EN, 2020. Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro. *bioRxiv*.
113. McNamara LA, MacNeil JR, Cohn AC, Stephens DS, 2018. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. *Lancet Infect Dis* 18: e272-e281.
114. Hsiang MS, Ntuku H, Roberts KW, Dufour M-SK, Whittemore B, Tambo M, McCreesh P, Medzihradsky OF, Prach LM, Siloka G, 2020. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low

- malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. *The Lancet* 395: 1361-1373.
115. Mitja O, Corbacho-Monne M, Ubals M, Tebe C, Penafiel J, Tobias A, Ballana E, Alemany A, Riera-Martí N, Perez CA, Suner C, Laporte P, Admella P, Mitja J, Clua M, Bertran L, Sarquella M, Gavilan S, Ara J, Argimon JM, Casabona J, Cuatrecasas G, Canadas P, Elizalde-Torrent A, Fabregat R, Farre M, Forcada A, Flores-Mateo G, Muntada E, Nadal N, Narejos S, Gil-Ortega AN, Prat N, Puig J, Quinones C, Reyes-Urena J, Ramirez-Viaplana F, Ruiz L, Riveira-Munoz E, Sierra A, Velasco C, Vivanco-Hidalgo RM, Sentis A, C GB, Clotet B, Vall-Mayans M, GROUP BP-C-R, 2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial. *Clin Infect Dis*.
116. Kulkarni S, Fisk M, Kostapanos M, Banham-Hall E, Bond S, Hernan-Sancho E, Norton S, Cheriyan J, Cope A, Galloway J, Hall F, Jayne D, Wilkinson IB, 2020. Repurposed immunomodulatory drugs for Covid-19 in pre-ICU patients - multi-Arm Therapeutic study in pre-ICU patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. *Trials* 21.
117. Lo Caputo S, Corso G, Clerici M, Santantonio TA, 2020. Baricitinib: A chance to treat COVID-19? *J Med Virol*.
118. Joshi R, Giri AP, Kulkarni MJ, Verma S, Chaudhary D, Deshmukh N, Chugh A, 2020. Rationale Based Selection and Prioritization of Antiviral Drugs for COVID-19 Management.
119. Xia C, Seo Y-J, Studstill CJ, Vijayan M, Wolf JJ, Hahm B, 2018. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. *Antiviral research* 158: 171-177.
120. 2020. Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). (MARACOVIC). Available at: <https://clinicaltrials.gov/ct2/show/NCT04441385?term=Maraviroc&cond=Covid19&draw=1&rank=1>. Accessed.
121. 2020. Maraviroc in Patients With Moderate and Severe COVID-19. Available at: <https://clinicaltrials.gov/ct2/show/NCT04435522?term=Maraviroc&cond=Covid19&draw=1&rank=3>. Accessed.
122. Gendrot M, Andreani J, Jardot P, Hutter S, Delandre O, Boxberger M, Mosnier J, Le Bideau M, Duflo I, Fonta I, Rolland C, Bogueau H, La Scola B, Pradines B, 2020. In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. *Molecules* 25.
123. Phillips JM, Gallagher T, Weiss SR, 2017. Neurovirulent murine coronavirus JHM. SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion. *Journal of virology* 91.
124. Vanlaere I, Libert C, 2009. Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. *Clinical microbiology reviews* 22: 224-239.
125. Wang X, Tu F, Zhu Y, Gao G, 2012. Zinc-finger antiviral protein inhibits XMRV infection. *PLoS One* 7: e39159.
126. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, Wang Q, Xu Y, Li M, Li X, 2020. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B*.
127. Zhu Y, Chen G, Lv F, Wang X, Ji X, Xu Y, Sun J, Wu L, Zheng YT, Gao G, 2011. Zinc-finger antiviral protein inhibits HIV-1 infection by selectively targeting multiply spliced viral mRNAs for degradation. *Proc Natl Acad Sci U S A* 108: 15834-9.
128. Wang WM, Gao Q, Jin XL, Zhou HY, 2007. [Malaria epidemic situation in Jiangsu Province in 2006]. *Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi* 25: 258-9.
129. Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, 2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. *Journal of Allergy and Clinical Immunology*.

130. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, 2020. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. New England Journal of Medicine.
131. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P, 2020. COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 20: 400-402.